To identify chromosomal regions that may include the loci of abnormally expressed cellular genes and may be specifically altered depending on the histological subtype of the tumor, we studied primary cervical carcinoma using CGH and HPV genotyping. Eighty-seven percent of the primary tumors were positive for DNA of a “high-risk” HPV type (e.g., 16 or 18). In the cervical carcinomas, without reference to histologic subtype, overrepresentation of chromosome 3q was the most consistent chromosomal aberration with underrepresentation of chromosome 3p also a frequent finding. Chromosome arms 1q, 5p, 20q, and Xq were overrepresented in many tumors and 3p loss and 5p, 8q, and 16q gain were only associated with squamous cell carcinoma in this series.
References
1.
KiviatNB, KoutskyLA, CritchlowCW, LorinczAT, CullenAP, BrockwayJ, HolmesKK. Prevalence and cytologic manifestations of human papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, and 56 among 500 consecutive women. Int J Gynecol Pathol11:197–203, 1992.
2.
zur HausenH.Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res49:4677–4681, 1989.
3.
MungerK, PhelpsWC, BubbV, HowleyPM, SchlegelR.The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol63:4417–4421, 1989.
4.
SmithPP, BryantEM, KaurP, McDougallJK. Cytogenetic analysis of eight human papillomavirus immortalized human keratinocyte cell lines. Int J Cancer44:1124–1131, 1989.
5.
MullokandovMR, KholodilovMG, AtkinNB, BurkRD, JohnsonAB, KlingerHP. Genomic alterations in cervical carcinoma: Losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res56:197–205, 1996.
6.
AtkinNB, BakerMC. Nonrandom chromosome changes in carcinoma of the cervix uteri. II. Ten tumors in the triploid-tetraploid range. Cancer Genet Cytogenet13:189–207, 1984.
7.
AtkinNB, BakerMC, FoxMF. Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet Cytogenet44:229–241, 1990.
8.
KallioniemiA, KallioniemiOP, SudarD, RutovitzD, GrayJW, WaldmanF, PinkelD.Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science258:818–821, 1992.
9.
HeselmeyerK, SchrockE, du ManoirS, BiegenH, ShahK, SteinbeckR, AuerG, RiedT.Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad SciU S A93:479–484, 1996.
10.
FergusonAW, Svoboda-NewmanSM, FrankTS. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol11:11–18, 1998.
11.
GarrettLR, Perez-ReyesN, SmithPP, McDougallJK. Interaction of HPV-18 and nitrosomethylurea in the induction of squamous cell carcinoma. Carcinogenesis14:329–332, 1993.
12.
SambrookJ, FritschEF, ManiatisT, Eds. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, pp9.16–9.19, 1989.
13.
AndersonS, SheraK, IhleJ, BillmanL, GoffB, GreerB, TamimiH, McDougallJ, KlingelhutzA.Telomerase activation in cervical cancer. Am J Pathol151:25–31, 1997.
14.
ManosMM, TingY, WrightDK, LewisAJ, BrokerTR. Use of polymerase chain amplification for the detection of genital human papillomavirus. Cancer Cells7:209–214, 1989.
15.
LunguO, WrightTCJr., SilversteinS.Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes6:145–152, 1992.
16.
KlingelhutzAJ, BarberSA, SmithPP, DyerK, McDougallJK. Restoration of telomeres in HPV-immortalized human anogenital epithelial cells. Mol Cell Biol14:961–969, 1994.
17.
WeberRG, SabelM, ReifenbergerJ, SommerC, OberstrassJ, ReifenbergerG, KiesslingM, CremerT.Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene13:983–994, 1996.
18.
PinkelD, StraumeT, GrayJW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A83:2934–2938, 1986.
19.
HurlinPJ, KaurP, SmithPP, Perez-ReyesN, BlantonRA, McDougallJK. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A88:570–574, 1991.
20.
KlingelhutzAJ, FosterSA, McDougallJK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature380:79–82, 1996.
21.
NakamuraTM, MorinGB, ChapmanKB, WeinrichSL, AndrewsWH, LingnerJ, HarleyCB, CechTR. Telomerase catalytic subunit homologs from fission yeast and human [see comments]. Science277:955–959, 1997.
22.
MeyersonM, CounterCM, EatonEN. EllisenLW, SteinerP, CaddieSD, ZiaugraL, BeijersbergenRL, DavidoffMJ, LiuQ, BacchettiS, HaberDA, WeinbergRA. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell90:785–795, 1997.
23.
TakakuraM, KyoS, KanayaT, TanakaM, InoueM.Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res58:1558–1561, 1998.
24.
KimNW, PiatyszekMA, ProwseKR, HarleyCB, WestMD, HoPL, CovielloGM, WrightWE, WeinrichSL, ShayJW. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science266:2011–2015, 1994.
25.
KohnoT, TakayamaH, HamaguchiM, TakanoH, YamaguchiN, TsudaH, HirohashiS, VissingH, ShimizuM, OshimuraM.Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene8:1825–1832, 1993.
